Open AccessJournal Article
Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia.
Steven G. Potkin,Rimal Bera,Bala Gulasekaram,Jerome Costa,S. Hayes,Y Jin,G. Richmond,D. Carreon,K. Sitanggan,B. Gerber +9 more
Reads0
Chats0
TLDR
Steady-state blood clozapine concentrations in 58 schizophrenic patients varied more than 45-fold (40-1911 ng/mL) after fixed-dose treatment (400 mg/day) and discriminated between responders and nonresponders optimally distinguished responders.Abstract:
Steady-state blood clozapine concentrations in 58 schizophrenic patients varied more than 45-fold (40-1911 ng/mL) after fixed-dose treatment (400 mg/day). Discriminant function analysis determined that a blood clozapine concentration of 420 ng/mL optimally distinguished responders from nonresponders. After 4 weeks of treatment, only 8% of those patients with a blood clozapine concentration 420 ng/mL. When plasma concentrations were increased above 420 ng/mL (by a double-blind random assignment procedure), nonresponders increased their response rate to 73% if their plasma concentrations at Week 12 exceeded 420 ng/mL compared with a response rate of 29% if their Week 12 levels remained below 420 ng/mL (chi 2 = 4.2, p < .04).read more
Citations
More filters
Journal ArticleDOI
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
Robert W. Buchanan,Julie Kreyenbuhl,Julie Kreyenbuhl,Deanna L. Kelly,Jason M. Noel,Douglas L. Boggs,Bernard A. Fischer,Seth Himelhoch,Beverly Fang,Eunice Peterson,Patrick R. Aquino,William R. Keller +11 more
TL;DR: An extensive literature review was conducted to determine whether the current psychopharmacological treatment recommendations required revision and whether there was sufficient evidence to warrant new treatment recommendations for prespecified outcomes of interest.
Journal ArticleDOI
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance
Alkomiet Hasan,Peter Falkai,Thomas Wobrock,Jeffrey A. Lieberman,Birte Glenthøj,Wagner F. Gattaz,Florence Thibaut,Hans-Jürgen Möller +7 more
TL;DR: These updated guidelines are based on a first edition of the World Federation of Societies of Biological Psychiatry Guidelines for Biological Treatment of Schizophrenia published in 2005 and provide evidence-based practice recommendations that are clinically and scientifically meaningful.
Journal ArticleDOI
Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis.
TL;DR: Clozapine is superior for treatment-refractory disorder but if there is no response by 6 months medications with lower adverse reactions should be considered.
Journal ArticleDOI
Dose response and dose equivalence of antipsychotics.
John M. Davis,Nancy Chen +1 more
TL;DR: Evidence from randomized, placebo-controlled studies of patients with schizophrenia or schizoaffective disorder, which compared 2 or more doses of an antipsychotic to calculate the dose-response curve is reviewed to find 3.3 to 10 mg haloperidol to be the near-maximal ED range.
Journal ArticleDOI
Clozapine versus typical neuroleptic medication for schizophrenia.
TL;DR: Clozapine is found to be more acceptable in long-term treatment than conventional antipsychotic drugs and typical neuroleptic drugs for broad outcomes such as mortality, ability to work or suitability for discharge at the end of the study.